Immune checkpoint inhibition to boost anti-tumor T cell responses are also being examined for efficacy in PDAC patients with clinical trials ongoing for anti-Cytotoxic T-Lymphocte-Associated Protein 4 (CTLA-4) (ipilimumab, tremilimumab), anti-PD1 (nivolumab, pembrolizumab), and anti-PDL1 (BMS-936559) blocking antibodies. Here, CD274 is linked to neoplasm.